GM&C leads £3m investment in Blueberry Therapeutics

Also participating in the round were San Francisco-based InClin Investments and a number of private investors.

The investment will support the progression of Blueberry's treatment for onychomycosis (fungal nail infection) and associated tinea pedis (athlete's foot), into clinical development. It will also hold a pre-investigational new drug meeting with the US Food and Drug Administration (FDA) to seek approval for its clinical development plans.

Company
Blueberry is a pharmaceutical company, using nanotechnology to create nanomedicines aimed at treating unmet clinical needs including skin diseases, antibiotic infections, inflammatory bowel disease, fungal infections and acute wounds.

The company is based in Alderley Park, Cheshire, and was founded in 2011.

People
GM&C Life Sciences Fund – Gareth King (investment manager).
Blueberry Therapeutics – John Ridden (CEO); Andrew Kay (chair).

Advisers
Equity – Ward Hadaway, Melanie Yeomans (legal).
Company – Slater Heelis, Simon Wallwark (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• Catapult Venture Managers
• Venture